Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28900865 | 0.91 | CA2 (0.36) | CA2CA9 | |
| SCHEMBL29655 | 0.91 | — | — | |
| SCHEMBL15349414 | 0.91 | CA2 (0.36) | CA2CA9 | |
| SCHEMBL5492896 | 0.89 | TSHR (0.32) | CA2CA9 | |
| Rubidium SCHEMBL2548472 | 0.88 | — | — | |
| SCHEMBL9055917 | 0.88 | — | — | |
| SCHEMBL2541678 | 0.88 | — | — | |
| SCHEMBL2548470 | 0.88 | — | — | |
| Hydrogen Sulfide SCHEMBL11041930 | 0.88 | — | — | |
| SCHEMBL2540927 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148838-A1 | Composition for Treatment and/or Prevention of a Corona Virus Infection | DR. KURT WOLFF GMBH & CO. KG (DE) | 2024-05-09 | — | — | US | disclosed |
| EP-4056234-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2024-04-17 | — | — | EP | disclosed |
| CN-117597134-A | Compositions for the treatment and/or prophylaxis of coronavirus infections | 库特沃夫博士有限及两合公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4304738-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023220097-A1 | ORGANIC RICINOLEATE SALTS AS DEODORIZING AGENTS | COLONIAL CHEMICAL, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230355668-A1 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | DR. KURT WOLFF GMBH & CO. KG (DE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023200773-A1 | COMPOSITIONS HAVING CAPSULES WITH A DUAL SHELL AND A NANOPARTICLE LAYER | THE PROCTER & GAMBLE COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230320949-A1 | Compositions Having Capsules | THE PROCTER & GAMBLE COMPANY | 2023-10-12 | — | — | US | disclosed |
| CN-116615180-A | Hydroxyapatite composition for the treatment and/or prevention of viral infections | 库特沃夫博士有限及两合公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4216970-A1 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-4051046-A | ANTISTATIC AGENTS, SOFTENERS, WRINKLE RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4011169-A | USING AN ENZYME AND AMINATED POLYSACCHARIDE | THE PROCTER & GAMBLE COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
| US-4000080-A | ETHYLENE OXIDE CONDENSATION PRODUCT WITH MALEIC ANHYDRIDE-VINYL METHYL ETHER COPOLYMER | THE PROCTER & GAMBLE COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3993573-A | SMECTITE CLAY, CATIONIC ANTISTATIC AGENTS AND ACIDIC COMPATIBILIZING AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3979339-A | POLYVINYL PYRROLIDONE, VINYL ACETATE-VINYL ALCOHOL COPOLYMER | THE PROCTER & GAMBLE COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3970594-A | SURFACTANT, BUILDER, POLYVINYL ALCOHOL OR PYRROLIDONE, POLYSACCHARIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
| US-3962152-A | SURFACTANT, ETHYLENE TEREPHTHALATE, POLYETHYLENE OXIDE TEREPHTHALATE | THE PROCTER & GAMBLE COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3954632-A | SMECTITE CLAY, QUATERNARY AMMONIUM ANTISTATIC AGENT, CARBOXYLIC ACID | THE PROCTER & GAMBLE COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| US-3944470-A | AMINATED POLYSACCHARIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
| US-3936537-A | QUATERNARY AMMONIUM COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320949-A1 | Compositions Having Capsules | ABCB11, ABCC1, ABCC9 | CA2 3134/4885CA9 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.